Speaker(s): 

Lauren Wagner, PharmD, Resident I, Pharmacy, Geisinger staff - has nothing to disclose.

Moderator(s): 

Sarah F. Hale, PharmD, BCPPS, Director of Pharmacy, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Evaluate the current literature and guidelines for prevention of myocardial infarction (MI) and stroke. 
• Described the efficacy of evolocumab in reducing major adverse cardiovascular events (MACE) in patients at high cardiovascular risk without a previous MI or stroke. 
• Discuss the clinical implications of using evolocumab for primary prevention in high-risk patients without established cardiovascular events.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brian Simpkins, PharmD, Jessica Milheim, CPhT, Clara Bishay, PharmD, and Simran Kaur, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.